Catalysts for Scemblix
13 tracked
Apr 30, 2026
phase 0 trial initiation
Washington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)
asciminib hydrochloride
→
Apr 25, 2026
phase 2 initiation
Novartis AG — asciminib hydrochloride (Phase II Trial Initiation)
asciminib hydrochloride
→
Nov 25, 2025
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 2, 2025
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Aug 7, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Jun 18, 2024
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Nov 8, 2023
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Jun 26, 2023
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 12, 2022
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2021
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→
Oct 29, 2021
approval
SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approval
asciminib hydrochloride
→